Drug survival analysis of etanercept compared with monoclonal antibody tumour necrosis factor-α inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a propensity score-matched analysis from the Czech ATTRA registry.

Š Tichý Lucie NekvindováJ BaranováJiri Vencovsky Karel Pavelka Pavel Horak Jakub Závada

Published in: Scandinavian journal of rheumatology (2024)

We found comparable survival in rheumatoid arthritis and ankylosing spondylitis. In psoriatic arthritis, we found significantly shorter survival on etanercept, possibly due to worse response of skin and nail manifestations.

Keyphrases

ankylosing spondylitis
rheumatoid arthritis
disease activity
monoclonal antibody
rheumatoid arthritis patients
free survival
systemic lupus erythematosus
interstitial lung disease
emergency department
juvenile idiopathic arthritis
adverse drug
electronic health record